PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE (COVID-19). KEMKES RI . REVISI KE-4. 27 Maret 2020
Tatalaksana COVID 19 di Rumah Sakit Rujukan
Terapi Suportif Dini dan Pemantauan
• Terapi suplementasi oksigen segera pada ISPA berat dan distress pernapasan, hipoksemia, atau
syok
• Terapi oksigen dimulai dengan pemberian 5 L/menit dengan nasal kanul dan titrasi
• untuk mencapai target:
• SpO2 ≥90% pada anak dan orang dewasa yang tidak hamil
• SpO2 ≥ 92%-95% pada pasien hamil
• Pemberian cairan konservatif pada pasien dengan ISPA berat tanpa syok.
• antibiotik empirik berdasarkan kemungkinan etiologi.
• Jangan memberikan kortikosteroid sistemik secara rutin untuk pengobatan pneumonia karena
virus atau ARDS di luar uji klinis kecuali terdapat alasan lain.
• Pemantauan ketat pasien dengan gejala klinis yang mengalami perburukan seperti gagal napas,
sepsis
• lakukan intervensi perawatan suportif secepat mungkin
• Pasien yang memiliki komorbid untuk menyesuaikan pengobatan dan penilaian prognosisnya
• Tatalaksana pada pasien hamil, dilakukan terapi suportif dan penyesuaian dengan fisiologi
kehamilan PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE (COVID-19). KEMKES RI . REVISI KE-4. 27 Maret 2020
Severity of illness and plan of management
SEVERITY OF ILLNESS PLAN
Mild illness without any risk factors/ • Outpatient care
Comorbidities • Strict Home Quarantine monitored by
government/health authorities
• Supportive care
• Assess patient’s clinical condition via telephonic
conversation/ using telemedicine facility
Moderate Illness: • Admit in Hospital isolation room
• Dyspnoea • Supportive care
• Hypoeximia • Start empirical antibiotics as per local community
• Infiltrates/ consolidation on chest acquired pneumonia treatment guidelines
xray/ CT scan • Oseltamivir 75/150mg BD
• Consider starting Hydroxychloroquine Or
Lopinavir/Ritonavir (If evident risk factors for
progression of disease are present)
INTERNATIONAL PULMONOLOGIST’S CONSENSUS ON COVID-19
Severity of illness and plan of management
SEVERITY OF ILLNESS PLAN
ACE2, angiotensin-
converting enzyme 2;
TMPRSS2, type 2
transmembrane serine
protease
• Resolution of symptoms
• Radiological improvement
• Documented virological clearance in 2 samples at least 24 hours apart
PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE (COVID-19). KEMKES RI . REVISI KE-4. 27 Maret 2020
INTERNATIONAL PULMONOLOGIST’S CONSENSUS ON COVID-19
Summary
• Infection control is an essential component of management of patients with
suspected or documented COVID-19.
• The optimal use of COVID-19-specific therapy is uncertain; no agent has clearly
proven effective.
• For most potential therapies, evidence on their use is low quality.
• For this reason, patients should be referred to clinical trials whenever possible.
• Clinicians should consult their own local protocols for management.
• For patients with nonsevere disease who have no laboratory features associated
with severe disease:
• Supportive care, with close monitoring for disease progression.
• For patients with severe (including critical) disease or with laboratory features
associated with severe disease
• strongly recommend referral to a clinical trial of remdesivir, convalescent
plasma, hydroxychloroquine, or lopinavir – ritonavir (Grade 1C).
• For critically ill patients who have features similar to cytokine release syndrome.
• interleukin (IL)-6 inhibitors have been proposed to disrupt the proinflammatory response.